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Seizures represent a common symptom in low-grade gliomas; when uncontrolled, they significantly 
contribute to patient morbidity and negatively impact quality of life. Tumor location and histology 
influence the risk for epilepsy. The pathogenesis of tumor-related epilepsy is multifactorial and may 
differ among tumor histologies (glioneuronal tumors vs diffuse grade II gliomas). Gross total 
resection is the strongest predictor of seizure freedom in addition to clinical factors, such as 
preoperative seizure duration, type, and control with antiepileptic drugs (AEDs). Epilepsy surgery 
may improve seizure control. Radiotherapy and chemotherapy with alkylating agents (procarbazine + 
CCNU + vincristine, temozolomide) are effective in reducing the frequency of seizures in patients with 
pharmacoresistant epilepsy. Newer AEDs (levetiracetam, topiramate, lacosamide) seem to be better 
tolerated than the old AEDs (phenobarbital, phenytoin, carbamazepine), but there is lack of evidence 
regarding their superiority in terms of efficacy. 
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Introduction 
 
Most patients with low grade gliomas (LGGs) experience epileptic seizures as a presenting symptom.1-
4 Clinically, tumor-related seizures manifest as simple or complex partial seizures with or without 
secondary generalization, and in more than 50%  of cases, are pharmacoresistant. When uncontrolled, 
tumor-related epilepsy affects patients’ quality of life, causes cognitive deterioration, and may result in 
significant morbidity.5,6 Preoperative seizures could reflect intrinsic glioma properties7 and are the 
most important factor associated with continued seizures after tumor surgery.8 Seizures and their 
sequelae can mimic tumor progression and prompt unwarranted interventions. A number of studies 
have established an association between epileptic seizures at disease onset and a more favorable 
prognosis.9-11 The management of seizures represent an important part of the management of LGG4,12 
and increasingly needs specific and multidisciplinary approaches. 
 
 
Factors predisposing to seizures  
 
Tumor location influences the risk for epilepsy.13 Tumors involving the frontal, temporal, and parietal 
lobes are more commonly associated with seizures than are occipital lesions. Infratentorial tumors 
rarely cause seizures. Intractable epilepsy is particularly frequent in tumors that involve the 
mesiotemporal and insular (paralimbic)  structures.14,15 This is linked to the high epileptogenicity of 
the temporal and insular cortex. Cortical tumors have a higher incidence of associated epilepsy than 
noncortical deeper lesions regardless of the involved lobe.15,16 Proximity to the rolandic fissure and the 
central sulcus also increases seizure frequency.  
The frequency of seizures differs widely according to tumor type. Glioneuronal tumors, such as 
gangliogliomas  (GGs) and disembryoplastic neuroepithelial tumors (DNTs), are typically associated 
with a chronic pharmacoresistant epilepsy in up to 90%–100% of patients.17 They occur 
predominantly in children and young adults and in the temporal lobe. These tumors are designated by 
World Health Organization (WHO)  classification18 as grade I tumors, thus most patients have a 
favorable outcome after surgical resection alone, with only rare cases of GGs that recur and/or 
undergo malignant transformation.19,20 Among DNTs, 2 histological variants, simple and complex, 
have been identified.21 Sometimes the differential diagnosis between these grade I tumors and the most 
common grade II gliomas is challenging due to sampling problems. The brain tissue adjacent to a GG 
or a DNT may frequently show an atypical cortical architecture due to a malformation of cortical 
development or cortical dysplasia 17,22; conversely, the presence of adjacent cortical maldevelopment is 
distinctly uncommon in grade II gliomas. Moreover, a dual pathology, such as hippocampal sclerosis 
in conjunction with the epileptogenic tumor, may occur. Other rare grade I gliomas, such as 
supratentorial pilocytic astrocytomas, pleomorphic xanthoastrocytomas, and angiocentric gliomas, 
which prevail in children and young adults, frequently cause seizures.17  
Diffuse LGGs (WHO grade II astrocytomas, oligodendrogliomas,  and oligoastrocytomas) present 
seizures in 60%–88% of patients.4,11 Among LGGs, seizures are much less frequent (47% vs 85%) in 
patients ≥60 years compared with younger patients.23 Patients with oligodendrogliomas and 
oligoastrocytomas, which more often involve the cortex, are more prone to seizures than those with 
astrocytomas, which tend to be situated in the white matter.15 The rare protoplasmic astrocytoma,  
which is predominantly cortically based, can be linked to chronic epilepsy. Among grade II 
astrocytomas,  a subtype characterized by long-term epilepsy, longer survival, and lower recurrence 
rate have been described.24 This subtype, called isomorphic astrocytoma,  is characterized by low 
cellularity, lack of mitotic activity,  highly differentiated astrocytic cells, absence of nuclear p53 
accumulation, and expression of glial microtubule-associated protein 2 and cluster of differentiation 
molecule 34.   
No correlation has been found between seizure activity and metabolic rate of the tumor measured by 
PET with methionine.11  
Unlike high-grade gliomas, LGGs presenting with seizures have been reported to be larger on MRI 
than those presenting with other neurological symptoms.25  
 
 
Mechanisms of epileptogenesis   
 
The pathogenesis of tumor-related seizures is multifactorial and still not fully understood.26,27 The 
mechanisms of epileptogenesis differ among tumor types.  
Intrinsic epileptogenicity of glioneuronal tumors is supported by electrocorticography and surgical and 
immunocytochemical studies, suggesting the presence of a hyperexcitable neuronal component.28 The 
cells of these developmental tumors can overexpress neurotransmitter receptors and neuropeptides, 
compromising the balance between excitation and inhibition.29 The associated dysplastic 
disorganization of the adjacent cortex contributes to the mechanism of seizure generation. An 
extensive inflammatory reaction with accumulation of microglial cells in the perilesional areas has 
also been suggested.30  
Slow-growing tumors could produce an epileptogenic milieu by partial deafferentation of cortical 
regions, thus causing a denervation hypersensitivity.13  
Studies using magnetoencephalographic recordings have shown that functional connectivity and 
network topology are significantly altered in diffuse LGG cases compared low-frequency connectivity 
(in particular the theta band) is pathologically increased, and the normal “small-world network” 
configuration is altered,31–33 thus leading to a lower threshold for seizures.34 These differences not only 
implicate the area around the tumor, but involve brainwide networks and are related to cognitive 
deficits.   
The role of changes in peritumoral tissue is being increasingly recognized.35 Neuronal density in the 
hippocampus of patients with mesial temporal lobe epilepsy and gliomas is normal; however, 
peritumoral cells may have an anomalous phenotype. Morphologic changes include aberrant migration 
with persistent neurons in the white matter, and pyramidal neurons with fewer inhibitory and more 
excitatory synapses. Intercellular connections between adjacent glial cells occur via connexin 
transmembrane gap junction proteins,  and immunohistochemical studies have found altered 
expression of connexins in tumor cells and reactive astrocytes of the perilesional cortex of patients 
with LGGs and epilepsy.36  
Modern neuroimaging techniques have provided new evidence that the peritumoral microenvironment 
in brain tumors is substantially different from that of normal brain tissue: MR spectroscopy has 
demonstrated decreased levels of N-acetylaspartate, a marker of neuronal viability and function, in 
lesional epileptogenic cortex.37 Several alterations predispose to seizure generation.  The tumor can 
mechanically compress the surrounding normal tissue because of mass effect,  inducing ischemia, 
hypoxia, and acidosis, which in turn induce glial cell swelling and damage. A functional consequence 
of acidic pH is the deregulation of sodium and calcium influx across cell membranes. Further, the 
influence of pH on the activity of antiepileptic drugs (AEDs) is uncertain. Changes in ionic 
concentrations can also contribute to neuronal excitability, and a focal disruption of the blood–brain 
barrier leads to the development of a seizure focus.38  
Brain tumors and peritumoral tissue have an altered expression of neurotransmitters and their 
receptors. A greater concentration of glutamate, the major excitatory amino acid neurotransmitter in 
the brain, has been found in brain tumor samples from patients with active epilepsy.39 When invading 
the normal tissue,  glioma cells could react to spatial constraints by releasing high levels of glutamate 
into the extracellular space, which induces seizures and later causes excitotoxic neuronal cell death, 
thereby facilitating invasion and migration.40–43 Ionotropic and metabotropic glutamate receptors have 
been shown to be overexpressed both in glioma cells and in peritumoral astrocytes.44–46 Activation of 
these receptors by glutamate could downregulate gamma-aminobutyric acid (GABA)–mediated 
inhibitory stimuli as a second mechanism of epileptogenesis. Alterations in levels of GABA, the main 
inhibitory neurotransmitter, may also contribute to tumor-associated seizures, but it remains unclear 
whether decreased inhibition or new excitatory activity, together with altered receptor subtype 
expression, is responsible for neuronal hyperexcitability.35  
Recent molecular–genetic findings have been described in glioneuronal tumors. A common role has 
been suggested for the phosphatidylinositol 3 kinase–mammalian target of rapamycin pathway in the 
pathogenesis of glioneuronal tumors, focal cortical dysplasias type IIB, and cortical tubers.47 Gene 
expression profiling of epilepsy-associated GGs has revealed alterations in the expression of genes 
involved in the immune system,  synaptic transmission, and cell cycle control.48 Overall,  it remains to 
be demonstrated that tumor-associated epilepsy and glioma growth have common genetic pathways.49  
Regarding diffuse LGGs, susceptibility candidate genes associated with tumor-related seizures have 
not yet been identified. In this regard, it has been reported that LGGs without LOH19q were more 
likely to present with seizures of secondary generalized type than those with LOH19q, thus suggesting 
that candidate genes could be located on chromosome 19q.50  
An actively discharging epileptic focus has the capability to induce a paroxysmal activity in areas of 
the brain distal to the original site and lead to a secondary epileptic focus, as occurs in cases of slow-
growing tumors of the temporal lobe and long history of seizures.  Both animal and human studies 
have demonstrated changes in synaptic plasticity and cerebral blood flow with prolonged epilepsy.51  
 
 
Factors influencing preoperative seizure control 
 
There is a lack of information on factors associated with preoperative seizure control in diffuse LGGs 
in the contemporary MRI era. In a recent large single-institution study, about half of patients had 
uncontrolled seizures.15 Associated with uncontrolled preoperative seizures were the presence of 
simple partial seizures, a longer duration from seizure onset, and temporal lobe involvement.  
Conversely, the presence of generalized seizures was associated with better seizure control. 
 
 Outcome after surgery 
 
Surgery allows seizure control in a significant proportion of cases of diffuse LGGs, including 
pharmacoresistant epilepsy.52–58 A recent study performed a systematic review of the published 
literature involving 773 patients in order to identify factors associated with seizure outcome after 
surgery.59 Overall, gross total resection was the strongest predictor of seizure freedom at a minimum 
follow-up of 6 months postsurgery: 71% of patients were seizure free (Engel class I), whereas 29% 
continued to have seizures (Engel classes II–IV). Interestingly, in one of the major series,15 the benefit 
in terms of seizure control was maintained at 12 months, and conversely only 9% of patients had no 
improvement or worsened. These results have improved dramatically over time as a result of the 
increased use of preoperative neuroimaging modalities (functional MRI, diffusion tensor imaging), 
intraoperative brain mapping techniques, and awake surgery, which allow more aggressive resections 
while preserving normal eloquent areas. Thus, in the modern era, resection can be accomplished 
according to functional boundaries,60,61 and gross total resection means resection of abnormalities of 
fluid attenuated inversion recovery (FLAIR) on MRI. Unfortunately, as the majority of LGGs tend to 
grow close to or within eloquent areas,62 a total or near total resection is feasible in no more than 45% 
of patients.61 Recently the concept of supratotal resection (ie, removal of a margin around FLAIR 
abnormalities) for better seizure control has been put forward.63 In addition to gross total resection, 
preoperative seizure history may also predict outcome.59 Patients whose seizures were well controlled 
by AEDs preoperatively and whose seizures were ≤1 year in duration achieved better seizure control 
postsurgery. The presence of nongeneralizing partial seizures was associated with poorer outcome. No 
significant difference in epilepsy outcome was found between temporal and extratemporal tumors and 
between adults and children. Second-line surgery can be useful for seizure control. In this setting,  
preoperative chemotherapy is being investigated.64,65  
Regarding glioneuronal tumors, similarly to diffuse gliomas, gross total resection has emerged as the 
strongest predictor of seizure freedom. At a minimum follow-up of 6 months after surgery 80% of 
patients were seizure free (Engel class I), whereas 20% continued to have seizures (Engel classes II–
IV).66 Moreover, early surgical intervention (3 years from onset of seizures) was associated with 
improved seizure outcome.67 Other factors positively associated with seizure control were ≤1 year 
duration of epilepsy and the absence of secondarily generalized seizures preoperatively. Outcome did 
not differ significantly between patients with temporal lobe versus extratemporal tumors, histologic 
diagnosis of GG versus DNT, and medically controlled versus refractory seizures before surgery.66 
Favorable seizure control has also been associated with factors such as younger age at surgery, 
presence of large nerve cells in the tumor specimen, and absence of postoperative epileptic 
discharges.19,68,69 Overall, among patients with temporal lobe epilepsy, long-term seizure control seems 
better in cases of glioneuronal tumors (94%) than of diffuse gliomas (79%) and cortical dysplasias 
(68%).70  
A major issue related to surgery, especially in temporal and paralimbic tumors, is that the 
epileptogenic zone can include significant extratumoral cortical areas.  Thus, 15%–20% of patients 
still suffer from refractory seizures after total tumor resection.55,57 In this setting the identification and 
removal of the epileptogenic zone beyond the tumor (ie, epilepsy surgery) could lead to an improved 
seizure outcome. Seizure outcome after lesionectomy versus lesionectomy + hippocampectomy,  
corticectomy, or both in patients with medically intractable seizures has been compared in several 
series, and improved seizure control after epilepsy surgery has been found.14,59,66,71–74 An open question 
remains regarding the use of intraoperative electrocorticography to identify the epileptogenic areas in 
epilepsy surgery. A series of studies tried to address this issue, leading to inconclusive 
results.14,15,59,66,75–77 It is generally recognized that the cases in which electrocorticography was used 
were associated with more severe and refractory epilepsy.  
 
 
Role of Radiotherapy, Chemotherapy, and Targeted Therapy  
 
Limited data are available regarding the impact of radiotherapy on tumor-related seizures. Stereotactic 
interstitial irradiation improves seizure control in 40%–100% of unresectable LGGs,78,79 and this could 
be due to an increased benzodiazepine receptor density.79 Gamma-knife radiosurgery is active in 
mesiotemporal tumor-related epilepsy80 and in patients with gelastic or generalized seizures from 
hypothalamic hamartomas.81,82 Conventional radiotherapy has been reported to be effective in seizure 
control in 72%–100% of patients with medically intractable epilepsy and LGGs.83,84 Patients may 
become seizure free (27%–55%), and the median duration of seizure control is ~12 months but can be 
as long as 8 years. An indirect suggestion of the efficacy of radiotherapy on epileptic seizures comes 
from the EORTC (European Organisation for Research and Treatment of Cancer) 22845 phase III 
trial, which compared adjuvant postoperative radiotherapy versus observation in LGGs. At 1 year, 
25% of patients who were irradiated had seizures, compared with 41% of patients who were not 
irradiated.85 After both interstitial and conventional radiotherapy, seizure reduction may begin early 
during radiotherapy and is not always associated with a tumor shrinkage on MRI. In fact, among 
patients who had a significant reduction of seizures after radiotherapy, ≤50% had stable disease on 
CT/MRI.83,84 Thus, in addition to a direct antitumor effect, ionizing radiation may decrease seizure 
activity by damaging epileptogenic neurons or inducing changes of the microenvironment in the 
peritumoral tissue.  
The efficacy of chemotherapy with alkylating agents  (procarbazine + CCNU + vincristine, 
temozolomide) in treating LGGs, either as salvage treatment after surgery and radiotherapy or as 
initial treatment after surgery in symptomatic/progressive patients, is well established.12 Seizure 
improvement has been obtained in 48%–100% of patients, with 20%–40% becoming seizure free.86–96 
Clinical improvement is more frequent than objective response on MRI. The majority of patients have 
hyperintense lesions on T2/FLAIR images with ill-defined margins and display a minor response or 
stable disease. Decreased seizure frequency seems to be better correlated with decrease of uptake of 
methionine on PET, whereas no significant correlation between seizure response and 1p/19q 
codeletion has been reported so far.96  
A significant decrease of epileptic seizures, in association with volume reduction on MRI, has been 
reported in subependymal giant-cell astrocytomas of tuberous sclerosis after treatment with the mTOR 
inhibitor everolimus.97,98  
 
 
Efficacy and Side Effects of Antiepileptic Drugs 
 
Studies regarding the impact of old AEDs (phenobarbital,  phenytoin, carbamazepine) on tumor-
related seizures are scarce. Overall, up to 70% of patients treated with these agents have recurrent 
seizures.99  
In the last 10 years there have been an increased number of papers focusing on the efficacy and 
tolerability of new AEDs in patients with brain tumors100–107;  however, they are all small series, either 
retrospective or prospective, that group together different histologies (high-grade gliomas and LGGs, 
metastases, meningiomas, etc). No papers have evaluated this issue in LGGs only.   
From a methodological point of view, when considering the efficacy of an AED, one should take into 
account the frequency of seizures, the phase of the disease (at diagnosis or at the time of progression), 
and the concomitant antineoplastic treatment (radiotherapy, chemotherapy)  that may contribute to the 
control of seizures. Unfortunately in the published studies these issues have not been addressed 
adequately. Thus, lack of studies in homogeneous subgroups of patients probably explains the wide 
range of seizure response that has been reported.   
In this review of the different series, we have tried to extrapolate the data regarding the efficacy of 
AEDs in LGGs. Table 1 summarizes the series in which these data are provided.   
Most reports are on levetiracetam.102–104,107 This drug, employed either as an add-on or as 
monotherapy,  has displayed a high rate of seizure response (75%–100%) with a good tolerance (mild 
drowsiness and dizziness in a few patients). Thus, levetiracetam may be a reasonable choice for the 
treatment of seizures in adults with brain tumors, particularly if concerns are raised about potential 
interactions with other medications, such as steroids or chemotherapeutic drugs.108 Two series have 
studied topiramate. Maschio et al.105 reported promising data in 13 cases of LGGs treated as add-on or 
monotherapy. The rate of response was 85% (with 7 of 13 patients seizure free), but 11 of 13 patients 
had received concomitant antineoplastic therapies (7 chemotherapy, 4 chemoradiotherapy), and the 
potential contribution of these treatments was not analyzed.  
  
 
 
 
 
Author 
AED 
Setting 
N
° of LGG 
Response rate (%
) 
O
ther treatm
ents 
M
edian follow‐up 
M
aschio, 2008 
TPM add‐on and m
onotherapy 
13/47 
54% (7/13) seizure‐free 
31% (4/13) significant response 
15% (2/13) unchanged 
7/13 chem
otherapy 
4/13 chem
otherapy + 
radioterapy 
2/13 out of treatm
ent 
16.5 m
onths 
Rudà, unpublished 
TPM add‐on in persisting seizures 
24/50 
8% (2/24) significant response 
14/24 out of treatm
ent 
9 m
onths 
W
agner, 2003 
LEV 
add‐on in persisting seizures 
8/26 
37.5% (3/8) seizure‐free 
37.5% (3/8) significant response 
25% (2/8) unchanged 
n. r. 
12.8 m
onths 
Rosati, 2010 
LEV 
as first‐line 
12/82 
100% (12/12) seizure‐free 
n. r. 
13.1 m
onths 
N
ew
ton, 2006 
LEV 
add‐on and m
onotherapy 
7/41 
43% (3/7) seizure‐free 
57% (4/7) significant response 
m
any patients on anti‐
neoplastic treatm
ents (not 
specified) 
4 w
eeks 
Striano, 2002 
TGB 
add‐on in persisting seizures 
10/11 
70% (7/10) significant response 
30% (3/10) seizure‐free 
n. r. 
12 m
onths 
M
aschio, 2011 
LCM 
add‐on 
3/14 
66.5% (2/3) seizure‐free 
33.5% (1/3) significant response 
1/3 TM
Z + bevacizum
ab 
1/3 TM
Z 
1/3 out of treatm
ent 
6 m
onths 
 
 
 
  
 
In our series (R. Ruda`, unpublished data), the setting was different: topiramate was employed as an 
add-on in patients with low-grade tumors and an active epilepsy with poor seizure control despite ≥1 
AED. Good seizure control was obtained in 8% of patients only. Tiagabine was investigated as an add-
on in 10 patients with LGG and drug-resistant partial epilepsy.101 A seizure reduction >50% was 
observed in 7 of 10 patients, with 3 patients becoming seizure free. Adverse events were seldom 
observed and did not lead to a discontinuation of the drug. More recently a small series was published 
on the use of lacosamide.109 In this prospective study, 14 patients were enrolled, including only 3 with 
LGGs. With a median follow-up of 6 months, the authors reported improved seizure control in all 
patients, with 2 of 3 being seizure free and 1 with a significant reduction of seizures. No side effects 
were reported. Overall, these studies suggest that side effects are less intense when newer, non-
enzyme-inducing AEDs are administered in cases of brain tumors. Merrel et al.110 reported a 
retrospective comparative series of 76 cases of glioma treated with levetiracetam or phenytoin. There 
was no difference in seizure outcome between the phenytoin and levetiracetam groups, while patients 
treated with levetiracetam experienced fewer side effects and required fewer non-seizure-related dose 
adjustments than patients treated with phenytoin. Switching from phenytoin to levetiracetam 
monotherapy for seizure control following surgery of gliomas was reported to be safe and feasible in a 
randomized phase II study.111  
In conclusion, the available data on the efficacy and tolerability of AEDs in tumor-related epilepsy are 
scarce and heterogeneous due to the different histologies, the pathophysiology of seizures, the natural 
history of the tumor, and concomitant treatments. Needed are prospective trials focused on specific 
drugs in specific tumor categories. In current clinical practice, non-enzyme-inducing AEDs should be 
the first choice in the treatment of LGG due to a lesser incidence of side effects and lack of potential 
interactions with other drugs (especially steroids and chemotherapeutics).99,112,113 Seizure control 
together with a reduction of side effects should be the primary goals of therapy in cases of LGG where 
tumors are compatible with long survival.  
  
 
Interactions between antiepileptic and anticancer agents   
 
Interactions have been reported between AEDs and chemotherapeutic drugs, based on shared 
cytochrome P450 drug metabolism.114 Potent inducers such as phenobarbital, phenytoin, primidone, 
and carbamazepine may significantly reduce serum levels of nitrosoureas, procarbazine, vincristine, 
cyclophosphamide, ifosfamide, paclitaxel, irinotecan, topotecan, 9-aminocampthotecin,  doxorubicin, 
teniposide, thiotepa, methotrexate, and busulfan.115,116 AED levels may also be affected by some 
chemotherapeutic agents, such as methotrexate, doxorubicin, adriamycin, and cisplatin, which 
decrease the serum levels of valproic acid, carbamazepine, and phenytoin. Demonstrating that 
temozolomide has minimal hepatic metabolism, one study documented no effect of temozolomide on 
levels of topiramate or oxcarbazepine in chronically treated patients.117  
Among targeted agents, bevacizumab, a monoclonal antibody against vascular endothelial growth 
factor that is under investigation in recurrent grade II gliomas after standard treatments (EORTC 
26091: TAVAREC), has a low potential for drug–drug interactions, whereas small tyrosine kinase 
inhibitor molecules (being investigated in clinical trials in malignant gliomas) such as imatinib, 
gefitinib, erlotinib, tipifarnib, and sorafenib are metabolized by the P450 system, thus leading to 
potential interactions with enzyme-inducing AEDs.118  
Valproic acid has distinct enzyme-inhibiting properties and might reduce the metabolism of a second 
drug, thereby raising plasma concentrations and potentially increasing the bone marrow toxic effects 
of concomitant chemotherapeutic drugs such as nitrosoureas.119  
Also, metabolism of corticosteroids is highly sensitive to enzyme induction.114 Enzyme-inducing 
AEDs increase the metabolism of various steroids, including dexamethasone, possibly resulting in 
inadequate control of peritumoral edema.  
 
 
 
 
Mechanisms of resistance to antiepileptic drugs   
 
The major reason for resistance of epilepsy to AEDs is overexpression of proteins belonging to the 
ATP-binding cassette (ABC) transporter family (in particular P-glycoprotein [P-gp]), which actively 
transport a variety of lypophilic drugs out of the brain capillary endothelium at the level of the BBB 
(the so called multidrug-resistance proteins [MRPs]). An overexpression of these proteins has been 
reported in tumor cells of patients with glioma120 and in samples of brain tissue from patients with 
ganglioglioma121, and could lead to a diminished drug transport into the brain parenchyma. Moreover, 
the release of glutamate upregulates P-gp expression.122 A number of AEDs, including phenytoin, 
phenobarbital, carbamazepine, lamotrigine, and felbamate, are substrates for P-gp123. Levetiracetam 
and valproic acid do not seem to represent a substrate for P-gp123-124, making these drugs attractive in 
brain tumor-associated epilepsy. Valproic acid might even reduce the expression of MRP1 via its 
histone deacetylase-inhibiting effects.125 
AEDs may fail to control seizures because of loss of receptor sensitivity13. 
 
The problem of prophylaxis  
Antiepileptic therapy in patients with brain tumors is recommended after the occurrence of a first 
seizure12,13. Two meta-analyses have found no evidence to support prophylaxis with phenobarbital, 
phenytoin or valproic acid in patients with no history of seizures126,127. A recent Cochrane review128 
has pointed out several pitfalls of  both meta-analyses and trials reviewed. The strength of evidence 
and recommendations are weakened by clinical heterogeneity among and within trials, 
misclassification of levels of evidence, and selection bias in the reporting of outcome (especially 
adverse events). Hence, the authors prefer to state that the evidence for seizure prophylaxis is 
inconclusive, at best. Nonetheless, regarding implications for practice, they agree with the American 
Academy of Neurology subcommittee126 that recommended against routine use of AEDs as 
prophylaxis in patients with brain tumors and advised discontinuance of AEDs >1 week postsurgery 
when used as a perioperative prophylaxis. However, many physicians still prescribe prophylactic 
AEDs, especially for prophylaxis of perioperative seizures129.   
It is unclear whether newer AEDs may have any benefit in preventing seizures. Only 2 retrospective 
trials are available. The first trial130 evaluated oxcarbazepine for prevention of early postoperative 
seizures, which occurred in <3%  of patients, and found similar data to those reported for old drugs; 
moreover, oxcarbazepine was well tolerated with rapid titration. The second study134 compared 
levetiracetam with phenytoin after supratentorial neurosurgery and found that the incidence of early 
and late seizures was similar in both groups but that significantly fewer adverse events occurred with 
the use of levetiracetam, resulting in a higher retention rate after 1 year. 
 
Conclusion   
LGGs are the most epileptogenic brain tumors. Total or near total surgical resection predicts better 
seizure outcome for most low-grade histologies. This supports early operation not only based on 
oncological considerations, but also to avoid the risk of chronic epilepsy and optimize the patient's 
quality of  life. However, no high-quality evidence, neither from randomized controlled trials nor from 
large registry studies, is available that addresses this question. Radiation and chemotherapy can be 
proposed when pharmakoresistant seizures still persist even if a true tumor progression is not evident.  
Newer AEDs seem to be better tolerated than the old drugs. Lastly, seizure control should always be a 
secondary endpoint in clinical trials in LGGs.  
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